drugset / Trial / NCT03194893
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
Timeline
- Start
- 2017-07-05
- Primary completion
- 2025-09-18
- Completion
- 2025-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alectinib | Small molecule | 600 mg | Oral |
| Subject | Crizotinib | Small molecule | 250 mg | Oral |